Abstract | OBJECTIVE: Compared with the 5HT(3) antagonist ondansetron, the NK(1) antagonist aprepitant has been shown in two double-blind trials to provide greater protection against postoperative vomiting and comparable or greater control of nausea. Post hoc analyses of pooled data from these trials were performed to more fully characterize the efficacy profile of aprepitant in terms of nausea and use of rescue therapy. RESEARCH DESIGN AND METHODS: MAIN OUTCOME MEASURES: RESULTS: In the 24 hours after surgery, aprepitant 40 mg was more effective than ondansetron for all five endpoints evaluated: (1) no significant nausea (56.4% vs. 48.1%); (2) no nausea (39.6% vs. 33.1%); (3) no vomiting (86.7% vs. 72.4%); (4) no nausea and no vomiting (38.3% vs. 31.4%); and (5) no nausea, no vomiting, and no use of rescue (37.9% vs. 31.2%) (p < 0.035 for the odds ratio for each comparison). Numerically more patients receiving aprepitant 125 mg also achieved these endpoints compared with ondansetron. CONCLUSIONS: These post hoc analyses confirm the favorable efficacy profile of aprepitant for the prevention of post operative nausea and vomiting.
|
Authors | Pierre Diemunsch, Christian Apfel, Tong J Gan, Keith Candiotti, Beverly K Philip, Jacques Chelly, Alexandra D Carides, Judith K Evans, Tony W Ho, Theodore Reiss |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 23
Issue 10
Pg. 2559-65
(Oct 2007)
ISSN: 1473-4877 [Electronic] England |
PMID | 17845742
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antiemetics
- Morpholines
- Aprepitant
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antiemetics
(therapeutic use)
- Aprepitant
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Morpholines
(therapeutic use)
- Postoperative Nausea and Vomiting
(prevention & control)
- Treatment Outcome
|